REGENXBIO Inc.
corporate_fare Company Profile
REGENXBIO Inc. (NASDAQ:RGNX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 36 items for RGNX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 18 rated 8 or above. Recent SEC coverage for RGNX spans 10-Q, 8-K, 424B5, FWP.
Recent high-impact activity:
- REGENXBIO 10-Q Flags Going-Concern Doubt Despite $251M Cash
- REGENXBIO Posts $0.62 Per-Share Q3 Loss as FDA Hold Weighs on Gene Therapy Pipeline
- REGENXBIO Settles ELEVIDYS Patent Litigation, Secures $39M Payment from Sarepta
- FDA Clinical Hold on RGX-121; BLA Resubmission Not Expected Near Term
- FDA Clinical Hold on RGX-121 Sends Regenxbio Down 22%
Financial Snapshot
Short Interest & Short Volume
8.29 days to coverFINRA reported short interest of 10,179,714 shares in RGNX as of the October 30, 2026 settlement, a 1.4% increase from the prior period — about 8.3 days to cover at its recent average daily volume. On November 20, 2026, 54.5% of RGNX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
High riskFiling-implied dilution signals for RGNX, detected from its recent SEC filings · based on capital-structure filings through 2026-07-20.
$100M Offering Priced at Deep Discount · Net Proceeds of ~$94M Extend Runway
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →